Melanoma

Article

Information resource about cancer clinical trials Melanoma Trial Results 1 Phase II Trial of Allovectin7® for Metastatic Melanoma site to take part in our clinical trials, please contact Cherie Smith, RN, by Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma Genetic and Clinical Study of Patients With Xeroderma Pigmentosum, Cockayne Nonprofit melanoma foundation that raises funds for research , public awareness and education against this lethal disease Founded in memory of Billy Graham those people and families which have been affected by Melanoma Melanoma Information>>Treatment>>Clinical Trials &nbsp Prevention Prevention for Everyone Science University Cancer clinical research, trials and studies conducted with Clinical Trials at The Norris Cotton Cancer Center Clinical Trials Melanoma Trials Support for Patients and Families Melanoma (Clinical Trials) Ganglioside Vaccine vs High dose Inteferon Alfa2b Vinblastine, Dacarbazine alone in Patients with Metastatic Malignant Melanoma Clinical Trials? Patients Chemotherapy, Radiation Treatment Melanoma Trials TITLE beta in the treatment of advanced melanoma, a skin cancer today was first tested in a clinical trial, a threestep research process Clinical Trials for Melanoma at Fox Chase Cancer Center This is database of clinical trials Melanoma Trial Results 1 Phase II Trial of Allovectin7® for Metastatic Melanoma site to take part in our clinical trials, please contact Cherie Smith, RN, by Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma Genetic and Clinical Study of Patients With Xeroderma Pigmentosum, Cockayne

Melanoma News

Provectus Pharmaceuticals Updates Shareholders on 2008 Accomplishments

Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, reports on its clinical and corporate accomplishments for 2008 in a letter to shareholders from Craig Dees, Ph.D., CEO of Provectus.

Immutep Announces Positive Interim Results In Phase I/II Chemoimmunotherapy Trial In Breast Cancer

Immutep S.A. announced today interim results from its ongoing Phase I/II chemoimmunotherapy clinical trial in metastatic breast carcinoma. ImmuFact IMP321 was administered the day after weekly paclitaxel for six months. The interim results show a clinical response rate of 50 per cent compared to 25 per cent with paclitaxel alone.

05.01.2009 - DJ HUGIN NEWS/Micromet Key Events for 2009

Corporate news announcement processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. =----------------------------------- =-------

Genta Summarizes Phase 2 Activity and Receives Orphan Drug Designation in Gastric Cancer for Tesetaxel, a Leading Oral ...

Genta Incorporated (OTCBB: GNTA) announced today that the Company has received notice from the U.S. Food and Drug Administration (FDA) that tesetaxel, the latest addition to Genta?s oncology product portfolio, has been granted designation as an ?Orphan Drug? for treatment of patients with advanced gastric cancer. Orphan drug status provides for a period of marketing exclusivity, certain tax ...

Micromet Key Events for 2009

Micromet, Inc. , a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, provides an outlook on key events anticipated for the year 2009.

CancerVax Resumes Enrollment in Phase 3 Clinical Trials of the CANVAXIN-TM- Therapeutic Cancer Vaccine For Melanoma.

Business Editors/Health/Medical Writers BIOWIRE2K CARLSBAD, CalifBUSINESS WIREApril 15, 2003 FDA Releases CANVAXIN(TM) Vaccine From Partial Clinical Hold CancerVax Corporation announced today that it will resume patient enrollment in its two international Phase 3 clinical trials of the CANVAXIN(TM)

Medarex Initiates Phase II Clinical Trials of MDX-010 for Metastatic Melanoma and Prostate Cancer.

- Enrollment Completed in 2 Phase I/II Melanoma Trials - Medarex, Inc. today announced the initiation of two Phase II clinical trials of MDX-010, one in patients with metastatic melanoma and one in patients with hormone refractory prostate cancer. The two randomized, multi-dose Phase II studies are

CancerVax Completes Planned Enrollment in Phase 3 Clinical Trial of Canvaxin for the Treatment of Stage III Melanoma.

CARLSBAD, Calif. - Phase 3 Trial for Stage IV Melanoma Continues to Enroll Patients CancerVax Corporation (NASDAQ:CNVX) announced today that it has completed the planned enrollment of 1,118 patients into its Phase 3 clinical trial of Canvaxin(TM) for the treatment of patients with Stage III

Oxxon Pharmaccines Melanoma Therapeutic Vaccine Enters Phase II Clinical Trials.

OXFORD, England - Oxxon Pharmaccines Ltd (Oxxon), a biotechnology company developing innovative immunotherapeutics, specifically therapeutic vaccines (pharmaccines), announced today that its melanoma pharmaccine has moved into Phase II clinical trials in the UK. The Phase I clinical trial

Genzyme Molecular Oncology Announces Initiation of Kidney Cancer and Melanoma Cancer Vaccine Clinical Trials.

Trials for Promising Fusion Cell Technology Expand FRAMINGHAM, Mass., Oct. 3 /PRNewswire/ - Genzyme Molecular Oncology (Nasdaq: GZMO) announced today the initiation of two phase 1-2 clinical trials - one in melanoma and one in kidney cancer - sponsored by investigators Donald Kufe, M.D.,